Literature DB >> 15618284

In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003.

Manuel Cuenca-Estrella1, Dolores Rodriguez, Benito Almirante, Juliette Morgan, Ana Maria Planes, Manel Almela, José Mensa, Ferran Sanchez, Josefina Ayats, Montserrat Gimenez, Margarita Salvado, David W Warnock, Albert Pahissa, Juan L Rodriguez-Tudela.   

Abstract

OBJECTIVES: The antifungal drug susceptibilities of 351 isolates of Candida species, obtained through active laboratory-based surveillance in the period January 2002-December 2003, were determined (Candida albicans 51%, Candida parapsilosis 23%, Candida tropicalis 10%, Candida glabrata 9%, Candida krusei 4%).
METHODS: The MICs of amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and caspofungin were established by means of the broth microdilution reference procedure of the European Committee on Antibiotic Susceptibility Testing. RESULTS AND
CONCLUSIONS: Amphotericin B and flucytosine were active in vitro against all strains. A total of 24 isolates (6.8%) showed decreased susceptibility to fluconazole (MIC > or = 16 mg/L) and 43 (12.3%) showed decreased susceptibility to itraconazole (MIC > or = 0.25 mg/L). Voriconazole and caspofungin were active in vitro against the majority of isolates, even those that were resistant to fluconazole.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15618284     DOI: 10.1093/jac/dkh548

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  40 in total

1.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

2.  Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.

Authors:  Laurent Arthur Decosterd; Bertrand Rochat; Benoît Pesse; Thomas Mercier; Frédéric Tissot; Nicolas Widmer; Jacques Bille; Thierry Calandra; Boris Zanolari; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

Review 3.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 4.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

5.  Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.

Authors:  M Cuenca-Estrella; A Gomez-Lopez; I Cuesta; O Zaragoza; E Mellado; J L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

6.  In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.

Authors:  Olivier Lortholary; Eric Dannaoui; Dorothée Raoux; Damien Hoinard; Annick Datry; André Paugam; Jean-Louis Poirot; Claire Lacroix; Françoise Dromer
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

7.  Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006.

Authors:  E Dannaoui; O Lortholary; D Raoux; M E Bougnoux; G Galeazzi; C Lawrence; D Moissenet; I Poilane; D Hoinard; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

Review 8.  Caspofungin: in pediatric patients with fungal infections.

Authors:  Karly P Garnock-Jones; Susan J Keam
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

9.  Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005.

Authors:  Guy St-Germain; Michel Laverdière; René Pelletier; Pierre René; Anne-Marie Bourgault; Claude Lemieux; Michael Libman
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-01       Impact factor: 2.471

10.  Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.

Authors:  A Gomez-Lopez; A Alastruey-Izquierdo; D Rodriguez; B Almirante; A Pahissa; J L Rodriguez-Tudela; M Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.